GRFS (grifols.com) Market Value to Book Value Ratio

Official company branding of Grifols SA (GRFS)

The market valuation dynamics for Grifols, S.A. (GRFS) on GURU.Markets correlate with the automation of plasma processing, although raw material collection remains a manual process. Grifols, S.A. (GRFS) leads the sector due to its unique network of centers and stable demand, which guarantees a high-quality cash flow. The current metric stands at 0.87, while the company successfully optimizes its debt load and refreshes management following audits, restoring the profitability of collection.

GRFS Grifols Biemat: Market Value to Book Value in the range 07/04/2022 - 10/28/2026
Original product of Grifols Group

Grifols, S.A. (GRFS) is undertaking large-scale investments in environmental plant modernization and the energy transition, which are impacting its asset structure and making the analysis of the market capitalization-to-book value ratio critical for assessing the business's real value. This metric on GURU.Markets measures the market premium over book value, allowing investors to differentiate fundamental growth from speculative volatility following earnings reports via the exchange capitalization-to-book value ratio.

Main competitors

argenx SE - Market Value to Book Value Ratio|BNTX (biontech.de) - Market Capitalization to Book Value|Market Value to Book Value Ratio abivax.com ABVX|Market Capitalization to Net Assets ADMA Biologics Inc|Protagonist Therapeutics Inc (PTGX) - Market Capitalization to Book Value Ratio|Market Value to Book Value Immunovant Therapeutics (IMVT)|Market Capitalization to Book Value Ratio KNSA (Kiniksa Pharmaceuticals)|adaptivebiotech.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Celldex Therapeutics, Inc. (CLDX)|AUPH: Market Value to Book Value|BCRX (BioCryst Pharmaceuticals Inc) - Market Value to Book Value Ratio|Vera Corp (VERA) - Market Cap to Net Assets Ratio|DNTH (Dianthus Therapeutics) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio pharvaris.com (PHVS)|AbCellera Bio (ABCL) - Market Cap to Net Assets Ratio|Market Value to Book Value Tourmaline Bio Inc (TRML)|Market Capitalization to Book Value Ratio PGEN|Pharming Corp - Market Capitalization to Book Value|NKTR: Market Value to Book Value Ratio|UPB: Market Cap to Net Assets Ratio|ZBIO (Zenas Biopharma) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Immunome Inc|GOSS (Gossamer Corp) - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio KALV|Market Value to Book Value Ratio Septerna Inc SEPN|Capitalization to Book Value Ratio pieris.com (PVLA)|SVRA: Market Capitalization to Book Value Ratio|Market-to-Book Ratio Rigel Pharma RIGL|Market Capitalization to Book Value Ratio ANAB|ATXS: Market Value to Equity Ratio|Market Value to Book Value Ratio enGene Holdings Inc. ENGN|rapt.com (RAPT) - Market Value to Book Value|JBIO: Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Aclaris Therapeutics Inc.|KYTX - Market Capitalization to Book Value Ratio|Market Capitalization to Net Assets TLSA (Tiziana Life Sciences, Ltd.)|CABA: Market Value to Book Value Ratio|ventyxbio.com - Market-to-Book Ratio|THTX - Market Value to Book Value Ratio|AVTX: Market Value to Book Value Ratio|Eledon - Market Value to Book Value Ratio|Market Capitalization to Book Value Agenus, Inc|CLYM - Market Cap to Net Assets Ratio|Market Value to Book Value ZURA|ATYR (aTyr Pharma) - Market Value to Book Value Ratio|Market Capitalization to Book Value adagene.com ADAG|Market Cap to Net Assets Ratio IMA|Market Capitalization to Book Value Shattuck Labs Inc STTK|Equillium Bio - Market Capitalization to Book Value Ratio|Connect Biopharma (CNTB) - Market Capitalization to Book Value Ratio|immunic-therapeutics.com - Market Cap to Net Assets Ratio|Atara Bio (ATRA) - Market Capitalization to Book Value|InflaRx NV - Market Capitalization to Book Value Ratio|Market Value to Equity Ratio XFOR|Adicet Bio (ACET) - Market Value to Book Value Ratio|Market Value to Book Value celularity.com (CELU)|INmune Bio (INMB) - Market Capitalization to Book Value Ratio|Barinthus Biotherapeutics PLC - Market Capitalization to Net Assets|Market Value to Book Value Ratio KZR (Kezar Life Sciences, Inc)|SABS: Market Capitalization to Book Value|Market Value to Book Value Ratio Akari Therapeutics (AKTX)|Enlivex Therapeutics Ltd. (ENLV) - Market Capitalization to Net Assets|QTTB - Market Capitalization to Book Value Ratio|Market Value to Book Value GeoVax Labs|Market Capitalization to Book Value Ratio EDSA|Market Capitalization to Book Value Ratio IBIO (iBio Corporation)|Market Value to Book Value Ratio Carisma Therapeutics Inc.|xtlbio.com - Market Value to Book Value|BOLT: Market Value to Book Value Ratio|HCWB - Market Cap to Net Assets Ratio|APVO: Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio aimimmuno.com|ADTX - Market Cap to Net Assets Ratio|Market Value to Book Value gribio.com|XRTX (XORTX Therapeutics) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value HIND (Vyome Holdings Inc.)|Revelation Bio - Market Value to Book Value Ratio|Indaptus Corp - Market Cap to Net Assets Ratio|SCNI: Market Value to Book Value Ratio|CalciMedica, Inc. (CALI) - Market Cap to Net Assets Ratio|AFMD: Market Cap to Net Assets Ratio|ALLK (Allakos) - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio HOOKIPA Pharma, Inc. (HOOK)|Capitalization to Book Value Ratio IGM Bio|iTeos Therapeutics - Market Capitalization to Book Value Ratio|Market-to-Book Ratio oceanbiomedical.com (OCEA)|TCBP (TC BioPharm) - Market Capitalization to Book Value Ratio|Third Harmonic Bio Inc. - Market Value to Equity Ratio